Abstract
Introduction Paliperidone, the major active metabolite of the atypical antipsychotic (AA) risperidone, is available in an oral extended-release (ER) formulation and is indicated for the acute and maintenance treatment of schizophrenia in adults. Materials and methods This article overviews the recommended dosing strategies for the treatment of schizophrenic patients in acute and chronic care settings. The efficacy, safety, pharmacology, pharmacokinetics, drug-drug interactions, and administration of paliperidone for schizophrenia are reviewed. Results Paliperidone's advanced-generation osmotic release delivery system makes it possible to avoid dosage adjustments when initiating therapy, and it may decrease the frequency of antidopaminergic effects that can occur with an immediate-release formulation. The recommended dose of paliperidone for the treatment of adults with schizophrenia is 6 mg every morning. Patients that receive daily doses ranging from 3 to 12 mg displayed generalized symptom improvement on the Positive and Negative Syndrome Scale (PANSS) and improved functioning on the Personal and Social Performance Scale. Discussion Paliperidone ER is a useful option in the treatment and prevention of the acute symptoms of schizophrenia. It may also be of use in patients with non-acute disease, including those previously treated unsuccessfully with other oral antipsychotics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
